Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Safety and Effectiveness of Rituximab Biosimilar CT-P10 during Routine Clinical Practice: Final Analysis of a Post-Marketing Surveillance Study in the Republic of Korea

Seok-Goo Cho, Jae-Cheol Jo, Young-Woo Jeon, Dajung Kim, Deok-Hwan Yang, Won Sik Lee, Yoon Seok Choi, Jun Ho Yi, Dok Hyun Yoon, Jee Hyun Kong, Jung-yoon Choe, Sung Hyun Kim, Keum Young Ahn, TaeHong Park, Jeongah Park, Sangeun Han

Blood (2022) 140 (Supplement 1): 10960–10962.

https://doi.org/10.1182/blood-2022-156478

Published: 2022

Journal Articles

Clinical Characteristics of Elderly Chronic Myeloid Leukemia Patients in Korea; Based on the National Health Information Database

Jee Hyun Kong, MD, Tae-Hwa Go, Jung Yeon Lee, MD, Jieun Uhm, MD PhD, Shin Young Hyun, MD

Blood (2018) 132 (Supplement 1): 4262.

https://doi.org/10.1182/blood-2018-99-116158

Published: 2018

Journal Articles

Pilot Prospective Phase II Study of Nilotinib Combined with Chemotherapy for Myeloid Blastic Phase of Chronic Myeloid Leukemia or Acute Myeloid Leukemia with BCR/ABL1

Hawk Kim, MD PhD, Yunsuk Choi, MD, Sung-Soo Yoon, MD PhD, Won-Sik Lee, Jee Hyun Kong, MD, Kyoo-Hyung Lee, MD PhD, Jeong-Yeal Ahn, MD, Sang Kyun Sohn, MD PhD

Blood (2018) 132 (Supplement 1): 3020.

https://doi.org/10.1182/blood-2018-99-116488

Published: 2018

Journal Articles

Final Study Results of Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 48 Months Follow-up

Blood (2018) 132 (Supplement 1): 1733.

https://doi.org/10.1182/blood-2018-99-110568

Published: 2018

Journal Articles

Adherence to Tyrosine Kinase Inhibitor Affects Overall Survival in Adult Korean Chronic Myeloid Leukemia Patients; Based on the National Health Information Database

Jee Hyun Kong, MD, Tae-Hwa Go, Jung Yeon Lee, MD, Hye Bin Song, Hohyung Nam, Jieun Uhm, MDPhD, Shin Young Hyun, MD

Blood (2018) 132 (Supplement 1): 1745.

https://doi.org/10.1182/blood-2018-99-111645

Published: 2018

Journal Articles

Deeper Molecular Response in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 36 Months Follow-up

Blood (2017) 130 (Supplement 1): 317.

https://doi.org/10.1182/blood.V130.Suppl_1.317.317

Published: 2017

Journal Articles

Outcomes after Sequential Tyrosine Kinase Inhibitors Treatment in Chronic Phase Chronic Myeloid Leukemia

Jee Hyun Kong, Elliott F. Winton, MD, Leonard Heffner, MD, Manila Gaddh, MD, Brittany Hill, PA-C, MMSc, MSc, MPH, Martha Arellano, MD, Fuad El-Rassi, Audrey Kim, Anand Jillella, MD, Vamsi K Kota

Blood (2017) 130 (Supplement 1): 1607.

https://doi.org/10.1182/blood.V130.Suppl_1.1607.1607

Published: 2017

Journal Articles

Characterization of ABL Compound Mutation Using Sanger and Subcloning Sequencing in Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia

Sukjoong Oh, Ki Hoon Kang, Won-Sik Lee, MD PhD, Hyeoung-Joon Kim, Jee Hyun Kong, Yunsuk Choi, MD, Young Rok Do, MD PhD, Jae-Yong Kwak, Sung-Hyun Kim, MD PhD, Jeong-A Kim, Dae Young Zang, MD PhD, Yeung-Chul Mun, MD PhD, Young-Woong Won, Sung-Eun Lee, MD, Dong-Wook Kim, MD PhD

Blood (2017) 130 (Supplement 1): 2864.

https://doi.org/10.1182/blood.V130.Suppl_1.2864.2864

Published: 2017

Journal Articles

The Impact of Early Molecular Response at 3 Months on Long-Term Survival Was Enhanced in the CP CML Patients Treated with Second-Generation Tyrosine Kinase Inhibitors

Sung-Eun Lee, MD, Won-Sik Lee, MD PhD, Hyeoung-Joon Kim, Jee Hyun Kong, Yunsuk Choi, MD, Young Rok Do, MD PhD, Jae-Yong Kwak, Sukjoong Oh, Sung-Hyun Kim, MD PhD, Jeong-A Kim, Dae Young Zang, Yeung-Chul Mun, MD PhD, Young-Woong Won, Dong-Wook Kim, MD PhD

Blood (2017) 130 (Supplement 1): 2873.

https://doi.org/10.1182/blood.V130.Suppl_1.2873.2873

Published: 2017

Journal Articles

Very Early Molecular Response at 1 Month Is a Predictor of the Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Won-Sik Lee, MD PhD, Hye-Young Song, Hyeoung-Joon Kim, Jee Hyun Kong, Young Rok Do, MD PhD, Jae-Yong Kwak, Sukjoong Oh, Sung-Hyun Kim, MD PhD, Jeong-A Kim, Dae Young Zang, MD PhD, Yeung-Chul Mun, MD PhD, Young-Woong Won, Sung-Eun Lee, MD, Yunsuk Choi, MD, Dong-Wook Kim, MD PhD

Blood (2017) 130 (Supplement 1): 1593.

https://doi.org/10.1182/blood.V130.Suppl_1.1593.1593

Published: 2017

Journal Articles

Outcomes of Chronic Phase Chronic Myeloid Leukemia (CP-CML) after Sequential Treatment with Tyrosine Kinase Inhibitors (TKI)

Jee Hyun Kong, Elliott F. Winton, MD, Leonard Heffner, MD, Manila Gaddh, MD, Brittany Hill, PA-C, MMSc, MSc, MPH, Martha L. Arellano, MD, Fuad El-Rassi, Audrey Kim, Vamsi Kota, MBBS

Blood (2017) 130 (Supplement 1): 5247.

https://doi.org/10.1182/blood.V130.Suppl_1.5247.5247

Published: 2017

Journal Articles

Outcomes of Chronic Phase Chronic Myeloid Leukemia Patients Following Tyrosine Kinase Inhibitors Dose-Reductions

Jee Hyun Kong, MD, Hanna Jean Khoury, MD, Elliott F. Winton, MD, Leonard T. Heffner, MD, Manila Gaddh, MD, Martha Arellano, MD, Fuad El-Rassi, MD, Audrey S Kim, RN, Anand Jillella, MD, Imre Bodó, MDPhD, Vamsi Kota, MD

Blood (2016) 128 (22): 3093.

https://doi.org/10.1182/blood.V128.22.3093.3093

Published: 2016

Journal Articles

Phase II Trial of R-CVP Followed By Rituximab Maintenance Therapy for Patients with Advanced Stage Marginal Zone Lymphoma- Consortium for Improving Survival of Lymphoma (CISL) Study

Blood (2016) 128 (22): 1811.

https://doi.org/10.1182/blood.V128.22.1811.1811

Published: 2016

Journal Articles

The Efficacy of JAK2 Inhibitor in Heavily Pretreated Classical Hodgkin Lymphoma: A Prospective Pilot Study of Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma

Seok Jin Kim, MD PhD, Hye Jin Kang, MD PhD, Shin Dong-Yeop, MD PhD, Ho Sup Lee, Sung Yong Oh, MD, Ho-Jin Shin, MD PhD, Dok Hyun Yoon, Jung Yong Hong, MD, Jee Hyun Kong, Kana Sakamoto, Young Hyeh Ko, MD, Kengo Takeuchi, MD PhD, Cheolwon Suh, Won Seog Kim

Blood (2016) 128 (22): 1820.

https://doi.org/10.1182/blood.V128.22.1820.1820

Published: 2016

Journal Articles

Randomized Phase II Multi-Center Trial of Busulfan, Etoposide, and Cyclophosphamide Versus Busulfan, Etoposide, and Melphalan As Conditioning Therapy for Autologous Transplantation in Patients with Non-Hodgkin's Lymphoma: A Multicenter Study from Consortium for Improving Survival of Lymphoma (CISL)

Kyoung Ha Kim, Lee Jae Hoon, Mark Lee, Kim Hoon-Gu, Young Rok Do, Yong Park, MD PhD, Sung Yong Oh, MD, Ho-Jin Shin, MD PhD, Won Seog Kim, Sung-Kyu Park, MD, Jong-Ho Won, Jee Hyun Kong, Moo-Rim Park, MD, Je-Jung Lee, Jae-Yong Kwak, Hye Jin Kang, MD PhD, Yeung-Chul Mun

Blood (2016) 128 (22): 3466.

https://doi.org/10.1182/blood.V128.22.3466.3466

Published: 2016

Journal Articles

Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients: 12 Months Result of Phase 3 Clinical Trial

Blood (2015) 126 (23): 476.

https://doi.org/10.1182/blood.V126.23.476.476

Published: 2015

Journal Articles

Predictive Value of 3-Month Early Molecular Response in New Chronic Phase Chronic Myeloid Leukemia Patients Treated with Radotinib

Blood (2015) 126 (23): 4053.

https://doi.org/10.1182/blood.V126.23.4053.4053

Published: 2015

Journal Articles

Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma

Seok Jin Kim, MD PhD, Hye Jin Kang, MD PhD, Dong-Yeop Shin, MD, Dok Hyun Yoon, Kana Sakamoto, MD, Jee Hyun Kong, MD, Young Hyeh Ko, MD PhD, Kengo Takeuchi, MD PhD, Cheolwon Suh, MD, PhD, Won Seog Kim, MD PhD

Blood (2014) 124 (21): 4443.

https://doi.org/10.1182/blood.V124.21.4443.4443

Published: 2014

Journal Articles

Clinical Outcomes of R-CHOP Chemotherapy Alone Compared with R-CHOP Plus Radiotherapy in Patients with Localized, Non-Bulky Diffuse Large B-Cell Lymphoma

Blood (2014) 124 (21): 4421.

https://doi.org/10.1182/blood.V124.21.4421.4421

Published: 2014

Journal Articles

Long-Term Assessment of Dasatinib-Induced Pulmonary Arterial Hypertension in Chronic Myeloid Leukemia

Jee Hyun Kong, Dr, Young-Woo Jeon, Sung-Eun Lee, Soo Young Choi, Soo-Hyun Kim, Yun Jeong Oh, Jin-Eok Park, Hye-Rim Jeon, Eun-Jung Jang, Suk Joong Oh, Dong-Wook Kim, MD PhD

Blood (2014) 124 (21): 5535.

https://doi.org/10.1182/blood.V124.21.5535.5535

Published: 2014

NARROW

Safety and Effectiveness of Rituximab Biosimilar CT-P10 during Routine Clinical Practice: Final Analysis of a Post-Marketing Surveillance Study in the Republic of Korea

Clinical Characteristics of Elderly Chronic Myeloid Leukemia Patients in Korea; Based on the National Health Information Database

Pilot Prospective Phase II Study of Nilotinib Combined with Chemotherapy for Myeloid Blastic Phase of Chronic Myeloid Leukemia or Acute Myeloid Leukemia with BCR/ABL1

Final Study Results of Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 48 Months Follow-up

Adherence to Tyrosine Kinase Inhibitor Affects Overall Survival in Adult Korean Chronic Myeloid Leukemia Patients; Based on the National Health Information Database

Deeper Molecular Response in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 36 Months Follow-up

Outcomes after Sequential Tyrosine Kinase Inhibitors Treatment in Chronic Phase Chronic Myeloid Leukemia

Characterization of ABL Compound Mutation Using Sanger and Subcloning Sequencing in Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia

The Impact of Early Molecular Response at 3 Months on Long-Term Survival Was Enhanced in the CP CML Patients Treated with Second-Generation Tyrosine Kinase Inhibitors

Very Early Molecular Response at 1 Month Is a Predictor of the Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Outcomes of Chronic Phase Chronic Myeloid Leukemia (CP-CML) after Sequential Treatment with Tyrosine Kinase Inhibitors (TKI)

Outcomes of Chronic Phase Chronic Myeloid Leukemia Patients Following Tyrosine Kinase Inhibitors Dose-Reductions

Phase II Trial of R-CVP Followed By Rituximab Maintenance Therapy for Patients with Advanced Stage Marginal Zone Lymphoma- Consortium for Improving Survival of Lymphoma (CISL) Study

The Efficacy of JAK2 Inhibitor in Heavily Pretreated Classical Hodgkin Lymphoma: A Prospective Pilot Study of Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma

Randomized Phase II Multi-Center Trial of Busulfan, Etoposide, and Cyclophosphamide Versus Busulfan, Etoposide, and Melphalan As Conditioning Therapy for Autologous Transplantation in Patients with Non-Hodgkin's Lymphoma: A Multicenter Study from Consortium for Improving Survival of Lymphoma (CISL)

Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients: 12 Months Result of Phase 3 Clinical Trial

Predictive Value of 3-Month Early Molecular Response in New Chronic Phase Chronic Myeloid Leukemia Patients Treated with Radotinib

Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma

Clinical Outcomes of R-CHOP Chemotherapy Alone Compared with R-CHOP Plus Radiotherapy in Patients with Localized, Non-Bulky Diffuse Large B-Cell Lymphoma

Long-Term Assessment of Dasatinib-Induced Pulmonary Arterial Hypertension in Chronic Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only